MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Acetaminophen

產(chǎn)品活性：Acetaminophen (Paracetamol) 是選擇性環(huán)氧合酶-2 (COX-2) 的抑制劑，IC₅₀ 值為 25.8 μM。Acetaminophen 是一種有效的肝 N-乙酰轉(zhuǎn)移酶 2 (NAT2) 抑制劑。Acetaminophen 是廣泛使用的解熱和止痛劑。

研究領(lǐng)域：Immunology/Inflammation  |  Epigenetics  |  Metabolic Enzyme/Protease  |  Anti-infection

作用靶點(diǎn)：COX  |  Histone Acetyltransferase  |  Endogenous Metabolite  |  Bacterial  |  Parasite

In Vitro: In vitro, acetaminophen elicites a 4.4-fold selectivity toward COX-2 inhibition (IC₅₀ 113.7 μM for COX-1; IC₅₀ 25.8 μM for COX-2). Following oral administration of the drug, maximal ex vivo inhibitions are 56% (COX-1) and 83% (COX-2). Acetaminophen plasma concentrations remaine above the in vitro IC₅₀ for COX-2 for at least 5 h postadministration. Ex vivo IC₅₀ values (COX-1: 105.2 μM; COX-2: 26.3 μM) of acetaminophen compared favorably with its in vitro IC₅₀ values. In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors. However, a >95% COX-1 blockade relevant for suppression of platelet function is not achieved. MTT assay shows that Acetaminophen (APAP) in a dose of 50 mM significantly (p<0.001) reduces cell viability to 61.5±6.65%. Interestingly, the significant (p<0.01) increase in cell viability to 79.7±2.47% is observed in the Acetaminophen/HV110 co-treated cells, compared to Acetaminophen treated cells.

In Vivo: Administering Acetaminophen (250?mg/kg, orally) to the mice causes significant (p<0.001) liver damage and necrosis of cells as evidenced by the elevated serum hepatic enzymes alanine aminotransferase (ALT), aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (γGT) compared with normal group. Conversely, effects of pretreatment with different doses of citral (125, 250, and 500?mg/kg) exhibited a significant (p<0.05) decrease in serum activities of ALT (91.79%, 93.07%, and 95.61%, resp.), AST (93.40%, 91.89%, and 96.52%, resp.), ALP (39.29%, 37.07%, and 59.80%, resp.), and γGT (92.83%, 91.59%, and 93.0%, resp.), when compared to the Acetaminophen group. Similar results were found in pretreatment with SLM on the activity of ALT (95.90%), AST (95.03%), ALP (70.52%), and γGT (92.69%).

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Fragment Library  |  Animal Disease Model Inducer Library  |  D-Valine-d₈  |  Antifungal agent 26  |  D-α-Hydroxyglutaric acid disodium  |  Nicotinamide N-oxide  |  (1R,2S,7R)-Sitafloxacin-d₄ (hydrochloride)  |  Quinidine-d₃  |  Nebacumab  |  Angulatin G  |  Acridine Orange base  |  N-Desethyl amodiaquine-d₅  |  Deoxycholic acid-d₅  |  Doxorubicin-¹³C,d₃ (TFA)  |  Gepotidacin  |  Amycolatopsin A  |  Palitantin  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ (sodium)  |  Adrenaline sulfate  |  Oleic acid-¹³C  |  Dextranase  |  Antimicrobial agent-5  |  Proguanil-d₆  |  NBTIs-IN-4  |  H2S Donor 5a  |  Proanthocyanidin  |  Azlocillin sodium salt  |  Methylmalonic acid  |  Antitubercular agent-13

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測(cè)分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證；
•   Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團(tuán)隊(duì)跟蹤新的制藥及生命科學(xué)研究進(jìn)展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機(jī)構(gòu)建立了長期的合作。